What are the next treatment options for a patient with anxiety and depression who has failed two selective serotonin reuptake inhibitors (SSRIs), a norepinephrine‑dopamine reuptake inhibitor (NDRI), and a serotonin‑norepinephrine reuptake inhibitor (SNRI)?

Treatment Options After Multiple Antidepressant Failures

For a patient with anxiety and depression who has failed two SSRIs, an NDRI, and an SNRI, the next step is to add psychotherapy (specifically cognitive behavioral therapy or dynamic interpersonal therapy) to the current or a switched antidepressant, as combination therapy significantly improves remission rates compared to medication alone. 1

Evidence-Based Treatment Algorithm

First Priority: Add Psychotherapy to Pharmacotherapy

The 2024 American College of Physicians guideline provides the strongest evidence for this approach 1. When dynamic interpersonal therapy (16 sessions) or general supportive therapy (16 sessions) was combined with SSRIs or SNRIs, remission rates reached 57.5% and 56.3% respectively, compared to only 31.0% with medication alone (P < 0.001). Response rates similarly improved to 78.7% and 78.1% versus 45.2% with monotherapy (P < 0.001).

This represents a clinically meaningful difference—nearly doubling the remission rate—making it the most impactful intervention at this stage.

Second Priority: Augmentation Strategies

If psychotherapy addition is not feasible or fails, consider pharmacologic augmentation:

Atypical Antipsychotics

• Aripiprazole has the strongest evidence from two placebo-controlled trials for treatment-resistant depression 2
• Quetiapine shows efficacy in low doses with similar effectiveness to SSRIs, though with lower tolerability 3
• Risperidone can reduce both depressive and anxiety symptoms 2

Common pitfall: Using antipsychotics as monotherapy rather than augmentation. These agents work best when added to existing antidepressants.

Anticonvulsants

• Pregabalin has the most robust evidence among anticonvulsants for anxiety, with rapid onset and low abuse potential 3
• Lamotrigine shows benefit, particularly if bipolar features are present 4

Third Priority: Switching Within or Between Classes

The 2023 ACP systematic review found that different switching strategies provide similar symptomatic relief 5. However, given your patient has already failed multiple classes:

• Consider switching to a different SSRI if only two were tried (there are 6+ available)
• Mirtazapine offers a different mechanism as a mixed antidepressant
• Tricyclic antidepressants (TCAs) may be more effective than SSRIs/SNRIs, particularly for comorbid chronic pain, though with greater side effect burden 4, 6

Fourth Priority: Bridging and Adjunctive Strategies

For acute anxiety symptoms while optimizing treatment:

• Short-acting benzodiazepines as a temporary "bridging strategy" during treatment transitions 4
• Avoid benzodiazepines if substance abuse history exists; use atypical antipsychotics instead 4
• Buspirone (azapirone) is FDA-approved for GAD with good evidence and lower abuse potential 3, 7

Critical Considerations

Treatment duration matters: Ensure each medication trial lasted at least 12 weeks at therapeutic doses before declaring failure 2. Many patients are switched prematurely.

Comorbidity assessment:

• Screen for bipolar disorder (requires mood stabilizer + antidepressant) 4
• Evaluate for substance use (changes benzodiazepine safety profile) 4
• Assess for chronic pain (favors duloxetine, TCAs, or gabapentin) 4

Stacking approach: For truly treatment-resistant cases, consider combining multiple mechanisms similar to hypertension management—for example, an SSRI + atypical antipsychotic + pregabalin 4. This aggressive approach is reserved for patients who remain significantly impaired despite sequential trials.

What NOT to Do

The evidence does not support:

• Olanzapine, quetiapine, ziprasidone, or risperidone augmentation for SSRI/SNRI-resistant generalized anxiety disorder (underpowered negative trials) 2
• Pindolol add-on for social anxiety (negative controlled trial) 2
• Continuing medication monotherapy indefinitely without adding psychotherapy 1

The certainty of evidence for most second-step comparisons is low 5, which is why the combination of psychotherapy with pharmacotherapy stands out—it has the most robust and recent evidence for improving outcomes in treatment-resistant cases.